This article is more than 5 years old. Information may no longer be current.

Eleven Biotherapeutics files registration statement for proposed IPO

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Eleven Biotherapeutics has filed a registration statement with the U.S. Securities and Exchange Commission related to a proposed initial public offering of shares of its common stock, according to a press release.

All shares of the stock in the offering will be sold by Eleven Biotherapeutics, a biopharmaceutical company that is developing protein therapeutics to treat diseases of the eye, although the number of shares to be offered and the price range have not been determined, the release said.

Citigroup, Cowen and Company, and Leerink Swann are joint book-running managers of the offering.